open access

Vol 11, No 2 (2007)
Prace oryginalne
Published online: 2007-05-18
Get Citation

Effect of once-weekly subcutaneous darbepoetin administration on blood pressure, kidney function and quality of live in anemic predialysis patients with chronic kidney disease

Maria Wanic-Kossowska, Andrzej Tykarski, Mikołaj Kobelski, Stanisław Czekalski
Nadciśnienie tętnicze 2007;11(2):123-129.

open access

Vol 11, No 2 (2007)
Prace oryginalne
Published online: 2007-05-18

Abstract

Background In this study we presented the results of anemia treatment with darbepoetin alfa in 18 patients with chronic kidney disease (3-5 stage of CKD) in predialysis period and its influence on blood pressure, quality of live and the rate of progression of chronic kidney disease.
Results After 10 weeks of darbepoetin alfa administration at the dose of 10 μg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoetin a treatment did not increased, in 4 out of 15 patients after 10 weeks of darbepoetin a treatment at the dose of 10 μg/week and in 7 after 15 weeks of the treatment at the dose of 7.5 μg/weeks hemoglobin serum level had increased over 13 g/dl. After 2 months without darbepoetin alfa treatment hemoglobin serum level had decreased but still maintain the target level of 11 g/dl. Darbepoetin alfa was well tolerated.
Conclusions Darbepoietin treatment did not change the blood pressure, significantly improved the quality of live but did not slow the progression of chronic kidney disease.

Abstract

Background In this study we presented the results of anemia treatment with darbepoetin alfa in 18 patients with chronic kidney disease (3-5 stage of CKD) in predialysis period and its influence on blood pressure, quality of live and the rate of progression of chronic kidney disease.
Results After 10 weeks of darbepoetin alfa administration at the dose of 10 μg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoetin a treatment did not increased, in 4 out of 15 patients after 10 weeks of darbepoetin a treatment at the dose of 10 μg/week and in 7 after 15 weeks of the treatment at the dose of 7.5 μg/weeks hemoglobin serum level had increased over 13 g/dl. After 2 months without darbepoetin alfa treatment hemoglobin serum level had decreased but still maintain the target level of 11 g/dl. Darbepoetin alfa was well tolerated.
Conclusions Darbepoietin treatment did not change the blood pressure, significantly improved the quality of live but did not slow the progression of chronic kidney disease.
Get Citation

Keywords

anemia; darbepoetin α; chronic kidney disease; hypertension; quality of life

About this article
Title

Effect of once-weekly subcutaneous darbepoetin administration on blood pressure, kidney function and quality of live in anemic predialysis patients with chronic kidney disease

Journal

Arterial Hypertension

Issue

Vol 11, No 2 (2007)

Pages

123-129

Published online

2007-05-18

Bibliographic record

Nadciśnienie tętnicze 2007;11(2):123-129.

Keywords

anemia
darbepoetin α
chronic kidney disease
hypertension
quality of life

Authors

Maria Wanic-Kossowska
Andrzej Tykarski
Mikołaj Kobelski
Stanisław Czekalski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl